Member Info for bob6

ex-divined on Thursday 9th NOVEMBER 19 pence paid on 11th JANUARY 2018 buy the shares up to close of business Wednesday 8th NOV. and get the dividend and if you like sell the shares on the ex-dividend day Thursday and still get the dividend but note the share price will be adjusted down by the dividend payment 19p before the market opens on THURSDAY 9th

http://www.morningstar.co.uk/uk/news/162294/glaxo-dividend-cut-unlikely-say-analysts.aspx

25 October 2017 GSK delivers Q3 sales of �7.8 billion, +4% AER, +2% CER Total EPS 24.8p, +49% AER, +46% CER; Adjusted EPS 32.5p, +3% AER, flat CER 25 October 2017 CDC�s Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up Committee recommends immunization for up to 62 million additional adults in the US .............................................................................................................................................. 62 MILLION 23 October 2017 Shingrix approved in the US for prevention of shingles in adults aged 50 and over Pooled clinical trial results showed > 90 percent efficacy across all age groups 18 October 2017 GSK receives World Health Organization Prequalification for Synflorix pneumococcal vaccine four-dose vial The World Health Organization (WHO) has awarded prequalification for the new four-dose vial prese... Read more 13 October 2017 GSK announces first approval of Shingrix in Canada ME HOW MANY MILLION The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over WHEN INVESTORS WORKOUT THE UP SIDE TO GSK WE MAY SEE A REVERSE OF -6%/7% SLIDE I MITE EVEN BUY SOME MORE AT THIS PRICE.

Glaxo is close to launching three new products, including shingles vaccine Shingrix and its once-daily inhaler for lung disease, both of which have secured regulatory approval. Having committed to pay 80p a share in dividends per year until 2018, the company will also announce a new dividend policy next year. Deutsche Bank thinks the dividend is secure, but believes "likely pressures on ViiV growth [HIV business] and a need to invest behind the pipeline limit scope for upside to this".

At least three buyout groups seen advancing in Unilever spreads auction: A team comprising Bain Capital and Clayton Dubilier & Rice along with private equity rivals KKR and Apollo are expected to move to the second round an auction for Unilever�s margarine and spreads business while two other private equity groups are no longer in the fray, sources said. - Reuters

Jefferies International today reaffirms its buy investment rating on Unilever PLC (LON:ULVR) and set its price target at 4830p.

EX-DIVIDEND ON THURSDAY 2nd NOVEMBER 2017 DIVIDEND PAYMENT OF 31.99p FOR EACH SHARE HELD UP TO CLOSE OF BUSINESS WEDNESDAY 1st NOVEMBER, PAYMENT WILL BE ON THE 13th DECEMBER 2017 YOU CAN BUY THE SHARES UP TO THE CLOSE OF BUSINESS WED 1st AND STILL GET THE DIVIDEND YOU CAN SELL THE SHARES ON THE EX-DIVIDEND DAY AND STILL GET THE DIVIDEND..

MY ACCOUNT CHARGES ARE �4.95 Shares, where there were 10 or more shares deals in the previous month �4.95 does that satisfy your curiosity.

1. ftse at a all time high and nobody really knows where it's going between now and the end of the year 2. ULVR sp this year 30/01/17 � 32.24 03/04/17 �39.22 11/08/ 17 �43.74 25/09/17 �42.69 today �41.27. I personally am going to wait and see what happens between now and mid December.

that's a fare comment to my post, the idea was to get new investors to think before jumping in as i have done in the past, caution is not a bad word, or when in doubt don't, is another. yes i agree it's just a dip for Unilever but are we at the bottom yet ?

https://www.google.co.uk/search?safe=active&q=ulvr+share+price&oq=ULVR+share+&gs_l=psy-ab.1.0.0i131k1j0l6j0i22i30k1l3.9277.33192.0.40875.27.22.0.0.0.0.247.2433.4j14j2.21.0....0...1.1.64.psy-ab..9.18.2296.6..35i39k1j0i20i263k1j0i67k1.139.JItfcVjlHYU don't get your fingers burnt , sp may drop a lot further yet

The 25 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,700.00, with a high estimate of 2,100.00 and a low estimate of 1,250.00. The median estimate represents a 16.92% increase from the last price of 1,454.00.

GlaxoSmithKline plc 10.5% Potential Upside Indicated by Deutsche Bank Posted by: Amilia Stone 21st September 2017 http://www.***************************/glaxosmithkline-plc-10-5-potential-upside-indicated-by-deutsche-bank/412735839

GlaxoSmithKline, alongside Innoviva, announced on Tuesday that the US Food and Drug Administration has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol under the brand name Trelegy Ellipta, for the long-term, once-daily, maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

, investors can snap up shares in the firm at a rock bottom valuation. Indeed, as noted above, shares in Glaxo are currently trading at a forward P/E of 13.3, 26% below the global pharmaceutical sector median valuation of 18. PRICE THEN WAS AROUND 1475 AND AT PRESENT PRICE 1454 THERE A GOOD INCOME INVESTMENT ( OVER SOLD)

Issued: London UK – LSE GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone furoate/ umeclidinium/vilanterol (FF/UMEC/VI) as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist (for effects on symptom control see section 5.1). The proposed brand name is Trelegy Ellipta.  13 September 2017 FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over Issued: London UK – LSE GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) voted unanimously that the data support the efficacy and safety of Shingrix for the prevention of herpes zoster (shingles) in adults ages 50 and over. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA, with the final decision on approval made by the FDA. 12 September 2017 GSK announces phase III results published in NEJM of mepolizumab in patients with eosinophilic COPD at risk of exacerbations - Regulatory filings planned for 2017 Issued: London, UK GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the publication of full results from the phase III studies for mepolizumab in chronic obstructive pulmonary disease (COPD). Data from the investigational clinical development programme showed that treating eosinophilic COPD patients with the biologic medicine, mepolizumab, in addition to maximal guideline-recommended therapy, reduced exacerbations in these difficult-to-treat patients. Based on the full data, discussions with external experts and the recognised unmet medical need in this patient population, regulatory filings are planned for 2017. Mepolizumab is not approved for use anywhere in the world for COPD.  11 September 2017 Positive results from pioneering Salford Lung Study in asthma published in The Lancet, and presented at European Respiratory Congress Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study. Issued: London  SEPTEMBER 2017 GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive results from the Salford Lung Study (SLS) in asthma have been simultaneously published in The Lancet journal and presented at the European Respiratory Society (ERS) International Congress in Milan. The innovative study, which reported headline results in May 2017, showed that initiation of once-daily Relvar Ellipta (fluticasone furoate ‘FF’/vila

We appreciate that results are backward looking and that medium term guidance is inspirational rather than hard fact, but Redrow had a record forward order book up 14% at £1.1bn. This suggests to us that performance is still climbing rather than reaching a plateau."

11p paid on 4 th November something to cheer us up wile SP recovers .

Jefferies International 08/09 Reiterates Buy Buy 606.00p

MARK WILSON INTERVIEW 2016 RESULTS https://www.aviva.com/media/video-interviews/2016-full-year-results-interview-group-ceo-mark-wilson/